1887

Abstract

A nonapeptide (16L1) was derived from the human papillomavirus type 16 (HPV-16) major capsid protein and tested for detection of potential cross-reactive serum IgG and cervical IgA antibodies in low- and high-risk HPV-associated low-grade squamous intraepithelial lesions (LSIL) and cervical cancer patients by ELISA. The IgG response was similar in women with low-risk HPV-associated LSIL and controls (=0·1). In contrast, more than 90 % of patients with high-risk HPV-associated LSIL were seropositive. Although tumours from cancer patients were all positive for the presence of high-risk HPV DNA, the level of seropositivity decreased significantly in this group (<0·0001). Cervical IgA antibodies were also detected in a significantly high proportion of women with high-risk HPV-associated LSIL compared with controls. However, the proportion of IgA-positive patients was lower than the proportion of IgG seropositives. In conclusion, the 16L1 peptide appears to be a high-risk type-common epitope that induces cross-reactive antibodies in high-risk, but not low-risk, HPV-associated LSIL patients, allowing differentiation of high- and low-risk infected women at this stage of infection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80077-0
2004-09-01
2020-01-26
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/9/vir852643.html?itemId=/content/journal/jgv/10.1099/vir.0.80077-0&mimeType=html&fmt=ahah

References

  1. Af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P., Pukkala, E., Schiller, J., Lehtinen, M. & Dillner, J. ( 1998; ). Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177, 1710–1714.[CrossRef]
    [Google Scholar]
  2. Andersson-Ellstrom, A., Dillner, J., Hagmar, B., Schiller, J., Sapp, M., Forssman, L. & Milsom, I. ( 1996; ). Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 23, 234–238.[CrossRef]
    [Google Scholar]
  3. Bosch, F. X., Manos, M. M., Muñoz, N. & 7 other authors ( 1995; ). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87, 796–802.[CrossRef]
    [Google Scholar]
  4. Calderon-Aranda, E. S., Selisko, B., York, E. J., Gurrola, G. B., Stewart, J. M. & Possani, L. D. ( 1999; ). Mapping of an epitope recognized by a neutralizing monoclonal antibody specific to toxin Cn2 from the scorpion Centruroides noxius, using discontinuous synthetic peptides. Eur J Biochem 264, 746–755.[CrossRef]
    [Google Scholar]
  5. Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J., Kiviat, N. & Galloway, D. A. ( 2000; ). Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181, 1911–1919.[CrossRef]
    [Google Scholar]
  6. Cason, J., Kambo, P. K., Best, J. M. & McCance, D. J. ( 1992; ). Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children. Int J Cancer 50, 349–355.[CrossRef]
    [Google Scholar]
  7. Chen, X. S., Garcea, R. L., Goldberg, I., Casini, G. & Harrison, S. C. ( 2000; ). Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5, 557–567.[CrossRef]
    [Google Scholar]
  8. Christensen, N. D., Kirnbauer, R., Schiller, J. T., Ghim, S. J., Schlegel, R., Jenson, A. B. & Kreider, J. W. ( 1994; ). Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205, 329–335.[CrossRef]
    [Google Scholar]
  9. Christensen, N. D., Dillner, J., Eklund, C., Carter, J. J., Wipf, G. C., Reed, C. A., Cladel, N. M. & Galloway, D. A. ( 1996; ). Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223, 174–184.[CrossRef]
    [Google Scholar]
  10. Dillner, J., Dillner, L., Utter, G., Eklund, C., Rotola, A., Costa, S. & DiLuca, D. ( 1990; ). Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Int J Cancer 45, 529–535.[CrossRef]
    [Google Scholar]
  11. Dillner, J., Wiklund, F., Lenner, P., Eklund, C., Fredriksson-Shanazarian, V., Schiller, J. T., Hibma, M., Hallmans, G. & Stendahl, U. ( 1995; ). Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 60, 377–382.
    [Google Scholar]
  12. Gausepohl, H., Boulin, C., Kraft, M. & Frank, R. W. ( 1992; ). Automated multiple peptide synthesis. Pept Res 5, 315–320.
    [Google Scholar]
  13. Giuliano, A. R., Papenfuss, M., Schneider, A., Nour, M. & Hatch, K. ( 1999; ). Risk factors for high-risk type human papillomavirus infection among Mexican–American women. Cancer Epidemiol Biomarkers Prev 8, 615–620.
    [Google Scholar]
  14. Heino, P., Skyldberg, B., Lehtinen, M., Rantala, I., Hagmar, B., Kreider, J. W., Kirnbauer, R. & Dillner, J. ( 1995; ). Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol 76, 1141–1153.[CrossRef]
    [Google Scholar]
  15. Karlsen, F., Kalantari, M., Jenkins, A., Pettersen, E., Kristensen, G., Holm, R., Johansson, B. & Hagmar, B. ( 1996; ). Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34, 2095–2100.
    [Google Scholar]
  16. Kaye, J. N., Cason, J., Pakarian, F. B., Jewers, R. J., Kell, B., Bible, J., Raju, K. S. & Best, J. M. ( 1994; ). Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. J Med Virol 44, 415–421.[CrossRef]
    [Google Scholar]
  17. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R. & Schiller, J. T. ( 1993; ). Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67, 6929–6936.
    [Google Scholar]
  18. Kirnbauer, R., Hubbert, N. L., Wheeler, C. M., Becker, T. M., Lowy, D. R. & Schiller, J. T. ( 1994; ). A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86, 494–499.[CrossRef]
    [Google Scholar]
  19. LeCann, P., Chabaud, M., Leboulleux, D. & 7 other authors ( 1995; ). Detection of antibodies to L1, L2, and E4 proteins of human papillomavirus types 6, 11, and 16 by ELISA using synthetic peptides. J Med Virol 45, 410–414.[CrossRef]
    [Google Scholar]
  20. Manos, M. M., Ting, Y., Wright, D. K., Lewis, A. J., Broker, T. R. & Wolinsky, S. M. ( 1989; ). Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7, 209–214.
    [Google Scholar]
  21. Melsheimer, P., Kaul, S., Dobeck, S. & Bastert, G. ( 2003; ). Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 47, 124–128.[CrossRef]
    [Google Scholar]
  22. Monroy-Garcia, A., Weiss-Steider, B., Hernandez-Montes, J. & 10 other authors ( 2002; ). Identification of two homologous antigenic peptides derived from L1 HPV-16 and -18 proteins specific for the HLA-B*3901 allele. Arch Virol 147, 1933–1942.[CrossRef]
    [Google Scholar]
  23. Parkin, D. M., Pisani, P. & Ferlay, J. ( 1999; ). Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80, 827–841.[CrossRef]
    [Google Scholar]
  24. Rocha-Zavaleta, L., Pereira-Suarez, A. L., Yescas, G., Cruz-Mimiaga, R. M., Garcia-Carranca, A. & Cruz-Talonia, F. ( 2003; ). Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology. Viral Immunol 16, 159–168.[CrossRef]
    [Google Scholar]
  25. Saiki, R. A., Bugawan, T. L., Horn, G. T., Mullis, K. B. & Erlich, H. A. ( 1986; ). Analysis of enzymatically amplified β-globin and HLA DQ alpha DNA with allele specific oligonucleotide probes. Nature 324, 163–166.[CrossRef]
    [Google Scholar]
  26. Shah, K. V., Viscidi, R. P., Alberg, A. J., Helzlsouer, K. J. & Comstock, G. W. ( 1997; ). Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 6, 233–237.
    [Google Scholar]
  27. Sharma, B. K., Ray, A. & Murthy, N. S. ( 1996; ). Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia. Eur J Cancer 32A, 872–876.
    [Google Scholar]
  28. Stoler, M. H., Rhodes, C. R., Whitbeck, A., Wolinsky, S. M., Chow, L. T. & Broker, T. R. ( 1992; ). Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 23, 117–128.[CrossRef]
    [Google Scholar]
  29. Uray, K., Price, M. R., Majer, Z., Vass, E., Hollosi, M. & Hudecz, F. ( 2003; ). Identification and solution conformation of multiple epitopes recognized by a MUC2 mucin-specific monoclonal antibody. Arch Biochem Biophys 410, 254–260.[CrossRef]
    [Google Scholar]
  30. Walboomers, J. M. M. & Meijer, C. J. L. M. ( 1997; ). Do HPV-negative cervical carcinomas exist? J Pathol 181, 253–254.[CrossRef]
    [Google Scholar]
  31. Walboomers, J. M. M., Jacobs, M. V. & Manos, M. M. ( 1999; ). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12–19.[CrossRef]
    [Google Scholar]
  32. Wang, Z., Hansson, B. G., Forslund, O., Dillner, L., Sapp, M., Schiller, J. T., Bjerre, B. & Dillner, J. ( 1996; ). Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J Clin Microbiol 34, 3056–3062.
    [Google Scholar]
  33. Wang, Z., Christensen, N., Schiller, J. T. & Dillner, J. ( 1997; ). A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78, 2209–2215.
    [Google Scholar]
  34. White, W. I., Wilson, S. D., Palmer-Hill, F. J. & 8 other authors ( 1999; ). Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73, 4882–4889.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80077-0
Loading
/content/journal/jgv/10.1099/vir.0.80077-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error